title: Effects of cimaterol on rabbit growth and myofibrillar protein degradation and on calcium-dependent proteinase and calpastatin activities in skeletal muscle.
abstract: The objectives of this study were to examine effects of a beta-adrenergic agonist (cimaterol) on growth and muscle development in rabbits and to examine cimaterol's effects on myofibrillar protein degradation (MPD) and on activities of several proteolytic enzymes including the calcium-dependent proteinases (CDP). Twelve New Zealand White rabbits were assigned to either control diets or to diets containing cimaterol for 35 d, after which they were killed and effects on performance and tissue weight gains were determined. Urine was collected from d 21 through 28 from each rabbit for assessment of N tau-methylhistidine (NMH) excretion. Cimaterol increased rates of gain, efficiency of gain and skeletal muscle weights. Enhancement in muscle weight was associated with an increase in total DNA and with a reduction in NMH. Cimaterol did not affect activities of cathepsin B, cathepsin D or neutral serine proteinase, but it reduced activities of the millimolar and micromolar forms of the CDP by 58 and 57%, respectively, and it reduced activity of the inhibitor of the CDP (calpastatin) by 52%. Cimaterol-dependent myofibrillar protein accretion was likely mediated, at least in part, by a reduction in MPD. The change in MPD was associated with a reduction in muscle CDP activities. Cimaterol-dependent muscle hypertrophy therefore may involve changes in calcium-dependent proteolysis of myofibrillar proteins. The significance of the effects of cimaterol on calpastatin activity is not known.
authors: Dept. of Anim, Sci., Oregon State University, Corvallis 97331-6702.
authors: N E
authors: NE
authors: Forsberg
authors: M A
authors: MA
authors: Ilian
authors: A
authors: A
authors: Ali-Bar
authors: P R
authors: PR
authors: Cheeke
authors: N B
authors: NB
authors: Wehr
mesh_terms: D000818:Animals; D002135:Calcium-Binding Proteins / Q000378:metabolism; D002154:Calpain / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004247:DNA / Q000032:analysis; D004983:Ethanolamines / Q000494:pharmacology*; D008099:Liver / Q000032:analysis; D008297:Male; D008762:Methylhistidines / Q000652:urine; D024510:Muscle Development; D009124:Muscle Proteins / Q000378:metabolism*; D009132:Muscles / Q000187:drug effects* / Q000378:metabolism; D009210:Myofibrils / Q000187:drug effects; D012313:RNA / Q000032:analysis; D011817:Rabbits / Q000254:growth & development* / Q000378:metabolism; D011897:Random Allocation; D015430:Weight Gain / Q000187:drug effects
chemical_list: D002135:Calcium-Binding Proteins; D004983:Ethanolamines; D008762:Methylhistidines; D009124:Muscle Proteins; D012313:RNA; C033668:calpastatin; D004247:DNA; D002154:Calpain; C028118:3-methylhistidine; C047411:cimaterol